MID1 and ovarian carcinoma: Selectivity was assessed for structurally unrelated Os(II) and Ru(II) complexes with cinnamic acid-derived ligands that were selective for ovarian cancer cells and had no impact on the proliferation of keratinocytes, fibroblasts (Hildebrandt et al., 2022).